Advertisement

Topics

Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine in an Elderly Population

2016-01-25 16:31:51 | BioPortfolio

Published on BioPortfolio: 2016-01-25T16:31:51-0500

Clinical Trials [3742 Associated Clinical Trials listed on BioPortfolio]

Long-Term Immunogenicity of the Norovirus GI.I/GII.4 Bivalent Virus-Like Particle (VLP) Vaccine in Adults

The purpose of this study is to evaluate descriptively the long-term immunogenicity of at least 1 Norovirus GI.1/GII.4 bivalent VLP vaccine (NoV) vaccine administration.

Serologic Assay Validation, Proficiency Testing Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine

The purpose of this study is to collect serum samples to evaluate serologic assays and to establish proficiency panels for serologic assays used for assessment of post vaccination immune r...

Efficacy and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-like Particle Vaccine in Adults

The purpose of this study is to evaluate the efficacy of the Norovirus (NoV) GI.1/GII.4 Bivalent Virus-Like Particle Vaccine against moderate or severe acute gastroenteritis (AGE) due to g...

Evaluation of Infectivity and Illness of Norwalk GI.1 Virus Lot 001-09NV in the Human Challenge Model

There is a need for safe, highly infectious Norovirus inocula for use in Norovirus vaccine-challenge studies to assess the efficacy of Norovirus vaccines and examine the immune response am...

Phase I Study to Determine the Optimal Human Challenge Dose for a Norovirus GII.4 Challenge Stock (CIN-1)

This is phase I, double blind, placebo-controlled safety and infectivity study of experimental human Norovirus genogroup GII.4 administered to healthy adults 18-49 years of age. Subjects s...

PubMed Articles [4512 Associated PubMed Articles listed on BioPortfolio]

Epidemiologic challenges in norovirus vaccine development.

Norovirus is the leading cause of acute gastroenteritis (AGE) worldwide. In the United States norovirus is estimated to cause 19-21 million illnesses, 1.7-1.9 million outpatient visits, 56,000-71,00...

Minimally Invasive Saliva Testing to Monitor Norovirus Infection in Community Settings.

Norovirus is a leading cause of acute gastroenteritis worldwide. Routine norovirus diagnosis requires stool collection. The goal of this study was to develop and validate a noninvasive method to diagn...

Detection of norovirus epidemic genotypes in raw sewage using next generation sequencing.

Noroviruses are a leading cause of epidemic and pandemic acute gastroenteritis (AGE) worldwide, and contaminated food and water are important routes for its transmission. Raw sewage has been used for ...

Structural and antiviral studies of the human norovirus GII.4 protease.

Norovirus is the leading cause of acute gastroenteritis worldwide with a yearly reported 700 million cases driving a $60 billion global socioeconomic burden. With no FDA approved therapeutics and the ...

Rotavirus VP6 as an Adjuvant for Bivalent Norovirus Vaccine Produced in .

Rotaviruses (RVs) and noroviruses (NoVs) are major causes of childhood acute gastroenteritis. During development of a combination vaccine based on NoV virus-like particles (VLP) and RV VP6 produced in...

Medical and Biotech [MESH] Definitions

A genus in the family CALICIVIRIDAE, associated with epidemic GASTROENTERITIS in humans. The type species, NORWALK VIRUS, contains multiple strains.

Water from natural sources which contain significant concentrations of dissolved salts such as sodium chloride.

A subclass of symporters that specifically transport SODIUM CHLORIDE and POTASSIUM CHLORIDE across cellular membranes in a tightly coupled process.

Agents that inhibit SODIUM CHLORIDE SYMPORTERS. They act as DIURETICS. Excess use is associated with HYPOKALEMIA.

The type species in the genus NOROVIRUS, first isolated in 1968 from the stools of school children in Norwalk, Ohio, who were suffering from GASTROENTERITIS. The virions are non-enveloped spherical particles containing a single protein. Multiple strains are named after the places where outbreaks have occurred.

More From BioPortfolio on "Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine in an Elderly Population"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial